Form 4: Akero Therapeutics CEO Andrew Cheng Sells Shares to Cover Tax Obligations

Akero Therapeutics CEO Andrew Cheng sold 7,894 shares of common stock on June 11, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On June 11, 2024, Andrew Cheng, the President and CEO of Akero Therapeutics, sold 7,894 shares of the company's common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted-average price of $22.641, with individual transactions ranging from $22.640 to $22.760.
• Following the transaction, Cheng directly owns 581,553 shares of Akero Therapeutics common stock.
• The sale was conducted under a 'sell-to-cover' policy adopted by the issuer, making the sales automatic and not at the discretion of the reporting person.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transaction is a routine sale of shares to cover tax obligations, which is a common practice and doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Sales by company executives are a normal part of corporate governance. It is important to consider the context of the sale, such as the reason for the sale and the amount of stock sold, in relation to the executive's total holdings.

Stakeholder Impact

• The sale of shares by the CEO could be perceived negatively by some shareholders, although it is a routine transaction to cover tax obligations.
• The company's 'sell-to-cover' policy ensures that tax obligations are met, which can be seen as a responsible approach to managing employee compensation.

Key Dates